Liminatus Pharma, Inc. Class A Common Stock
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Chris Kim
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 12611 Hiddencreek Way Cerritos CA United States of America 90623
- IPO Date
- May 1, 2025
- CIK
- 0001971387
- Website
- liminatuspharma.com
- Similar Companies
- Business
- Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company focused on developing novel immune-modulating cancer therapies, including its lead candidate IBA101, a humanized anti-CD47 monoclonal antibody with IgG4 Fc designed to block the CD47-SIRPα interaction, promote macrophage-mediated phagocytosis of tumor cells, and target advanced solid tumors such as non-small cell lung cancer while minimizing anemia and thrombocytopenia risks associated with first-generation CD47 inhibitors; a high-affinity humanized anti-CD47 antibody aimed at restoring innate immune cell anti-tumor function without inducing hemagglutination or hemolysis; chimeric antigen receptor (CAR)-T cell therapies; and a Guanylyl Cyclase C (GCC) cancer vaccine in Phase II for metastatic colorectal, pancreatic, gastric, and esophageal cancers expressing GCC. Founded in 2018 and headquartered at 6 Centerpointe Drive, Suite 625, La Palma, California, the company operates in the immuno-oncology segment of the biotechnology industry, targeting patients with solid tumors through therapies originating from collaborations with Thomas Jefferson University and South Korea's Innobation Bio. In October 2025, Liminatus entered a Memorandum of Understanding with New Zealand-based Capital Trust Group Limited for up to $30 million in equity financing via an earn-out mechanism to advance its research and development programs, including next-generation CD47-blockade therapies, with definitive agreements targeted for November 2025 and potential future digital bond financing discussions.
Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline
Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds
Liminatus Pharma Announces Nasdaq Delisting Notification
Liminatus Pharma Announces Nasdaq Delisting Notification
Liminatus Pharma Is Trending Overnight — Here's Why LIMN Stock Surged Over 79% In After-Hours Session
Athira Pharma (NASDAQ:LONA) and Liminatus Pharma (NASDAQ:LIMN) Head to Head Analysis
Reviewing Athira Pharma (NASDAQ:LONA) & Liminatus Pharma (NASDAQ:LIMN)
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody
Financial Contrast: Athira Pharma (NASDAQ:LONA) and Liminatus Pharma (NASDAQ:LIMN)
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
Comparing Liminatus Pharma (NASDAQ:LIMN) & Inhibikase Therapeutics (NASDAQ:IKT)
Liminatus Pharma (NASDAQ:LIMN) vs. Inhibikase Therapeutics (NASDAQ:IKT) Head-To-Head Contrast
Liminatus Pharma (NASDAQ:LIMN) and Inhibikase Therapeutics (NASDAQ:IKT) Head-To-Head Survey
Critical Survey: Inhibikase Therapeutics (NASDAQ:IKT) versus Liminatus Pharma (NASDAQ:LIMN)
Analyzing Liminatus Pharma (NASDAQ:LIMN) and Inhibikase Therapeutics (NASDAQ:IKT)
Financial Analysis: Inhibikase Therapeutics (NASDAQ:IKT) and Liminatus Pharma (NASDAQ:LIMN)
Reviewing Vor Biopharma (NASDAQ:VOR) and Liminatus Pharma (NASDAQ:LIMN)
Liminatus Pharma (NASDAQ:LIMN) versus Prime Medicine (NASDAQ:PRME) Head to Head Comparison
Analyzing Prime Medicine (NASDAQ:PRME) and Liminatus Pharma (NASDAQ:LIMN)
Head to Head Analysis: Liminatus Pharma (NASDAQ:LIMN) versus Vor Biopharma (NASDAQ:VOR)